Petmed Express Q2 2026 earnings

PETS · 2026-11-10 16:17 AMC ET · 8-K on SEC

Net sales declined 19.4% YoY to $35.8M, widening the net loss to $6.4M as operating expenses remained high.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$35.8M-19.4%-12.7%Ex. 99.1, income statement
EPS (GAAP)$(0.31)+24.4%+10.7%Ex. 99.1, income statement
EPS (adjusted)$(0.34)+31.0%+5.9%Ex. 99.1, income statement
Adj. EBITDA$(3.6M)+23.9%+5.9%Ex. 99.1, income statement
Adj. EBITDA margin-10.2%+2.5 pp+0.7 ppEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 27.4% (prior 28.0%, change -0.6 pp)
  • Operating expenses $16.2M (+22.0% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 0.2% (prior-year 0.1%, year-to-date 0.2%)
  • Non-GAAP bridge Adds back stock-based compensation, income taxes, depreciation and amortization, interest expense, employee severance, and professional fees.

KPIs

MetricActualPrior quarterPrior yearChange
Cost to acquire a new customer-32%-15%N/A+17 pp YoY
Inventories$6.3M$13.6M$31.9M-53.7% QoQ, -80.2% YoY
Cash and cash equivalents$11.4M$21.4M$36.1M-46.7% QoQ, -68.4% YoY

Guidance

not stated in the 8-K

What drove it

  • Revenue story Net sales decreased 19.4% YoY to $35.8M, driven by a decline in prescription medication sales and higher consumer promotional usage.
  • EPS story The net loss widened to $6.4M, or $(0.31) per share, driven by lower gross profit and higher operating expenses.
  • One-off check None stated for the current quarter.

The good

  • Cost to acquire a new customer decreased 32% YoY
  • Adjusted EBITDA margin improved 2.5 pp YoY

The bad

  • Net sales declined 19.4% YoY
  • Net loss widened to $6.4M
  • Operating expenses increased 22.0% YoY

The ugly

  • none

Open questions

  • What specific actions are being taken to reverse the decline in prescription medication sales?
  • How will the company achieve sustainable profitability given the current operating expense levels?
Full release

Petmed Express (PETS) earnings release, November 10, 2026

Petmed Express Inc (PETS) · Form 8-K, Item 2.02 · Filed · SEC filing

PetMeds® Announces Second Quarter Financial Results

Delray Beach, Florida, November 10, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026.

Quarterly Highlights

• For the second quarter ended September 30, 2026, net sales were $35.8 million compared to $44.4 million for the prior year period, a decrease of 19.4%, primarily driven by a decline in prescription medication sales and higher consumer promotional usage.

• Net loss for the quarter ended September 30, 2026, was $6.4 million, or $(0.31) per diluted share, compared to a net loss of $8.5 million, or $(0.41) per diluted share, for the prior year period. The decrease in net loss was primarily driven by lower general and administrative expenses and advertising expenses. These favorable factors were partially offset by lower gross profit primarily driven by unfavorable product mix shift and lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order.

• Adjusted EBITDA¹ was $(3.6) million compared to $(2.3) million in the prior year period.

“We have stabilized the operations of the business and our focus now is on transforming our core direct-to-consumer pharmacy business and making PetMeds a leaner, more profitable company at the size we are today,” said Jeff Willard, Chief Executive Officer and President of PetMeds. “We are already making progress: this quarter we cut our cost to acquire a new customer by 32% from a year ago. Next, we are repositioning the brand so pet parents know exactly why to choose PetMeds, making our marketing work harder, making our website easier to buy from, and keeping more of the customers we win. Every one of these steps is built to create a profitable PetMeds that can grow again.”

Earnings Webcast

PetMeds will host a webcast reviewing financial results for the second quarter ended September 30, 2026 at 4:30pm Eastern Time today. The webcast can be accessed at the “News & Events” section of the Company’s investor relations website at https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx or directly here.

About PetMed Express, Inc.

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com

Forward Looking Statement

Financial statements

Income Statement

Three Months Ended September 30, — (In thousands, except for share and per share amounts) (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Six Months Ended September 30, – 2026Six Months Ended September 30, – 2025
Net sales35,77044,36476,78595,544
Cost of sales25,96731,94955,64968,726
Gross profit9,80312,41521,13626,818
Operating expenses:
General and administrative11,96814,17623,16527,124
Advertising2,0724,3416,29210,387
Depreciation and amortization2,1822,2784,3304,561
Impairment of goodwill and intangible assets27,258
Total operating expenses16,22220,79533,78769,330
Loss from operations-6,419-8,380-12,651-42,512
Other income:
Interest (expense) income, net-195-326-533-524
Other, net194195632382
Total other (expense) income-1-13199-142
Loss before provision for income taxes-6,420-8,511-12,552-42,654
Provision for income taxes1492718
Net loss-6,434-8,520-12,579-42,672
Basic and diluted net loss per share-0.31-0.41-0.6-2.05
Basic and diluted weighted-average common shares outstanding21,072,15520,889,12421,059,84320,822,270

Income Statement

Three Months Ended — PetMed Express, Inc. ($ in thousands, except percentages)

Three Months Ended – September 30, 2026 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:Three Months Ended – September 30, 2025 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:Increase (Decrease) – $ – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:Increase (Decrease) – % – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:
Net loss-6,434-8,5202,08624.0%
Add (subtract):
Share-based Compensation Expense3262487831.0%
Income Taxes149556.0%
Depreciation and Amortization2,1822,278-96-4.0%
Interest Expense (Income), Net195326-131-40.0%
Employee Severance741,223-1,149-94.0%
Professional Fees (1)2,120-2,120-100.0%
Adjusted EBITDA-3,643-2,316-1,327-57.0%

Income Statement

Six Months Ended — PetMed Express, Inc. ($ in thousands, except percentages)

Six Months Ended – September 30, 2026 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:Six Months Ended – September 30, 2025 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:Increase (Decrease) – $ Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:Increase (Decrease) – % Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:
Net loss-12,579-42,67230,09371.0%
Add (subtract):
Share-based Compensation Expense524839-315-38.0%
Income Taxes2718950.0%
Depreciation and Amortization4,3304,561-231-5.0%
Interest Expense (Income), Net53352492.0%
Employee Severance741,319-1,245-94.0%
Professional Fees (1)3,141-3,141-100.0%
Impairment of goodwill and intangible assets27,258-27,258-100.0%
Adjusted EBITDA-7,091-5,012-2,079-41.0%

Balance Sheet

(In thousands, except for share and per share amounts)

September 30, 2026 – (Unaudited)March 31, 2026
Current assets:
Cash and cash equivalents11,41821,412
Accounts receivable, less allowance for credit losses of $0 and $25, respectively1,3731,908
Inventories6,30313,608
Prepaid expenses and other current assets6,1876,378
Prepaid income taxes62258
Total current assets25,34343,564
Noncurrent assets:
Property and equipment, net23,47226,326
Intangible and other assets, net10,31010,789
Operating lease right-of-use assets278512
Total noncurrent assets34,06037,627
Total assets59,40381,191
Current liabilities:
Accounts payable15,25820,906
Sales tax payable18,92722,261
Accrued expenses and other current liabilities7,3027,665
Current operating lease liabilities291493
Deferred revenue588689
Income taxes payable20
Total current liabilities42,36652,034
Deferred tax liabilities, net175175
Operating lease liabilities, net of current lease liabilities42
Total liabilities42,54152,251
Preferred stock, $0.001 par value, 5,000,000 shares authorized:
Convertible preferred stock, $0.001 par value, with a liquidation preference of $4 per share, 250,000 shares authorized; 2,500 and 2,500 convertible shares issued and outstanding, respectively99
Common stock, $.001 par value, 40,000,000 shares authorized; 22,131,508 and 21,385,638 shares issued and outstanding, respectively2221
Additional paid-in capital20,14719,647
Retained earnings-3,3169,263

Cash Flow

Six Months Ended September 30, — (In thousands) (Unaudited)

Six Months Ended September 30, – 2026Six Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-12,579-42,672
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization4,3304,561
Impairment of goodwill and intangible assets27,258
Share-based compensation524839
Bad debt (recovery) expense6
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable535346
Inventories7,3051,437
Prepaid income taxes19636
Prepaid expenses and other current assets191-1,031
Operating lease right-of-use assets234225
Accounts payable-5,648-4,445
Sales tax payable-3,334416
Accrued expenses and other current liabilities-133-23
Lease liabilities-244-228
Deferred revenue-101-1,090
Income taxes payable-20-80
Net cash used in operating activities-8,744-14,445
Cash flows from investing activities:
Purchases of property and equipment-1,227-3,916
Net cash used in investing activities-1,227-3,916
Cash flows from financing activities:
Dividends paid-23
Cash paid for tax withholding on net settlement of restricted stock-23-238
Net cash used in financing activities-23-261
Net decrease in cash and cash equivalents-9,994-18,622
Cash and cash equivalents, at beginning of period21,41254,720
Cash and cash equivalents, at end of period11,41836,098
Supplemental disclosure of cash flow information:
Cash paid for income taxes, net of refunds-13766
Dividends payable in accrued expenses and other current liabilities1
Non-cash investing activity for property and equipment additions-230-854

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, filed on June 2, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.¹

Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.

Investor Contact:

ICR, LLC

Reed Anderson

(646) 277-1260 investor@petmeds.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Petmed Express earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.